

Reblozyl®

(luspatercept-aamt)
for injection 25mg • 75mg

You are invited

Please join us for an educational program focusing on:

A first-line treatment option for adults with anemia due to lower-risk MDS

Thursday, April 11, 2024 at 6:00 PM - PST

FEATURING:

Yvonne Bossert, DNP, MSN-Ed, RN

Exec Clinical Nurse Consultant
Bristol Myers Squibb

LOCATION:

Left Bank Santana Row
377 Santana Row #1100
San Jose, California 95128

To register, please scan the QR code or visit

<https://myattendeeresource.com/BMS/240411-BMS-97257>



OR CONTACT

NAME: Diana Mendell

EMAIL: diana.mendell@bms.com

or call 1-866-326-7600 during the hours of 8:30 AM to 5:00 PM
ET, Monday–Friday, and refer to meeting ID **240411-BMS-97257**

TOPICS

WILL ADDRESS:

- First-line efficacy and safety data from the COMMANDS clinical trial
- Urgent treatment needs in patients with lower-risk MDS
- Dose adjustments to optimize patient response

MDS=myelodysplastic syndromes.

INDICATION

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Please see page 2 for Important Safety Information and the link to the US Full Prescribing Information for REBLOZYL.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombosis/Thromboembolism

In adult patients with beta thalassemia, thromboembolic events (TEE) were reported in 8/223 (3.6%) of REBLOZYL-treated patients. TEEs included deep vein thrombosis, pulmonary embolus, portal vein thrombosis, and ischemic stroke. Patients with known risk factors for thromboembolism (splenectomy or concomitant use of hormone replacement therapy) may be at further increased risk of thromboembolic conditions. Consider thromboprophylaxis in patients at increased risk of TEE. Monitor patients for signs and symptoms of thromboembolic events and institute treatment promptly.

Hypertension

Hypertension was reported in 11.4% (63/554) of REBLOZYL-treated patients. Across clinical studies, the incidence of Grade 3 to 4 hypertension ranged from 2% to 9.6%. In ESA-naïve adult patients with MDS with normal baseline blood pressure, 23 (36%) patients developed SBP \geq 140 mm Hg and 11 (6%) patients developed DBP \geq 80 mm Hg. Monitor blood pressure prior to each administration. Manage new or exacerbations of preexisting hypertension using anti-hypertensive agents.

Embryo-Fetal Toxicity

REBLOZYL may cause fetal harm when administered to a pregnant woman. REBLOZYL caused increased post-implantation loss, decreased litter size, and an increased incidence of skeletal variations in pregnant rat and rabbit studies. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 3 months after the final dose.

ADVERSE REACTIONS

Grade \geq 3 (\geq 2%) adverse reactions included hypertension and dyspnea.

The most common (\geq 10%) all-grade adverse reactions included diarrhea, fatigue, hypertension, peripheral edema, nausea, and dyspnea.

LACTATION

It is not known whether REBLOZYL is excreted into human milk or absorbed systemically after ingestion by a nursing infant. REBLOZYL was detected in milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because many drugs are excreted in human milk, and because of the unknown effects of REBLOZYL in infants, a decision should be made whether to discontinue nursing or to discontinue treatment. Because of the potential for serious adverse reactions in the breastfed child, breastfeeding is not recommended during treatment and for 3 months after the last dose.

DRUG ABUSE POTENTIAL

Abuse: Abuse of REBLOZYL may be seen in athletes for the effects on erythropoiesis. Misuse of drugs that increase erythropoiesis, such as REBLOZYL, by healthy persons may lead to polycythemia, which may be associated with life-threatening cardiovascular complications.

Please see [US Full Prescribing Information for REBLOZYL](#).